Business Wire

NC-VERANEX

Share
Veranex Announces Acquisition of IMMR

Veranex , the first concept-to-commercialization global service provider dedicated to the MedTech industry, today announced the acquisition of IMMR , a leading preclinical science organization that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators. IMMR is located in Paris, France.

Formed in June 2021 with global growth investor Summit Partners , Veranex provides the global medical technology industry with comprehensive and integrated solutions and services that accelerate the product life cycle to help improve the lives of patients everywhere. As a result of this acquisition, Veranex gains state-of-the-art, FDA-inspected and AAALAC-accredited facilities and extensive in-house expertise, enhancing Veranex’s services for preclinical studies worldwide.

“We are excited to welcome the world-class and market leader IMMR to Veranex,” said Patrick K. Donnelly , Executive Chairman at Veranex. “Veranex is focused on the needs of the MedTech industry and this acquisition enhances our long-term ability to meet the end-to-end needs of MedTech companies in one organization. Veranex’s clients will benefit from IMMR’s 30-plus years of experience in the design and conduct of preclinical studies, expertise in complex cardiovascular and non-cardiovascular procedures, and state-of-the-art surgical suites and husbandry facilities, all unparalleled for leading successful completion of sophisticated studies with novel interventional or surgical technologies.”

“As part of a combined company with a full range of product development, regulatory, and market access expertise, our partnership with Veranex complements our vision to help clients achieve their objectives and advance important MedTech innovations that significantly improve patient care,” said IMMR Founding Partner and Scientific Director Luc Behr , D.V.M., Ph.D. “IMMR adds another dimension of expertise and services to Veranex to enable and accelerate research in the industry.”

IMMR’s unique, highly efficient, and full service approach — with studies that are carefully planned, expertly conducted to the highest ethical standards, and professionally documented — saves money and reduces time to market.

“IMMR excels in procedures ranging from early feasibility studies through to GLP studies to support global regulatory approvals,” added IMMR Founding Partner and Scientific Director Nicolas Borenstein , D.V.M., Ph.D. “With our expert team of professionals, our worldwide clientele enjoys high success rates with their medical technology innovations.”

For this transaction, financial advisors were Clearwater International and Cain Brothers , a division of KeyBanc Capital Markets, and Gide Loyrette Nouel , a leading international law firm located in Paris, served as legal counsel. Financial terms of the transaction were not disclosed.

About Veranex

Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept through to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its integrated and comprehensive solutions unify the entire development process. For more information, visit VeranexSolutions.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Logical Intelligence Introduces First Energy-Based Reasoning AI Model, Signals Early Steps Toward AGI, Adds Yann LeCun and Patrick Hillmann to Leadership21.1.2026 19:21:00 CET | Press release

Logical Intelligence, an artificial intelligence company developing energy-based (EBM) reasoning systems, today announced that Kona 1.0, its pioneering EBM for reasoning, will enter pilot programs with select partners in the energy, advanced manufacturing, and semiconductor industries later this quarter. Logical Intelligence also released a live demonstration of Kona 1.0 on its website, beginning with head-to-head sudoku challenges against leading large language models. Additional demonstrations, including chess and Go, are planned. The company said the goal is to give researchers and the public a clear view into how energy-based reasoning differs from probabilistic systems. “Kona learns by recognizing and correcting its own mistakes, rather than guessing the most likely answer,” said Eve Bodnia, founder and CEO of Logical Intelligence. “If general intelligence means the ability to reason across domains, learn from error, and improve without being retrained for each task, then we are s

Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership21.1.2026 17:35:00 CET | Press release

Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tribunal. This decision has no impact on the commercialization of Galderma’s neuromodulator portfolio. Galderma will continue to commercialize and supply Dysport®/Azzalure®, Alluzience®, and RelfydessTM in all territories where it has regulatory approval and in accordance with our existing agreements with our partner Ipsen. Progressing on our path towards becoming the undisputed dermatology powerhouse Galderma remains focused on its ambition to become the world’s undisputed dermatology powerhouse across the full spectrum of a fast-growi

ThetaRay Appoints Financial Markets Technology Leader Brad Levy as Chief Executive Officer21.1.2026 17:00:00 CET | Press release

Former Symphony CEO to lead ThetaRay’s next phase of AI-driven category leadership in transaction monitoring and due diligence ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced the appointment of Brad Levy as Chief Executive Officer. Levy, a leading financial markets infrastructure executive and former CEO of Symphony, will lead ThetaRay’s next phase of growth as the company continues to scale its Cognitive AI platform, now emerging as the leading AI strategy and technology for transaction monitoring and transaction due diligence, across banks and fintechs worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121002476/en/ ThetaRay Appoints Brad Levy as CEO Levy brings decades of experience building and leading mission-critical financial infrastructure at scale. Most recently, he served as CEO of Symphony, the financial markets infrastructure and technology platform established by a

HCL Group and UpLink Announce Winners of ‘Water Resilience Challenge’ Under the Aquapreneur Innovation Initiative21.1.2026 16:02:00 CET | Press release

10 Aquapreneurs selected from over 300 applicantsWinners showcased innovations across digital water management, biological breakthroughs, hardware solutions, deep-tech design, and community-driven modelsFinancial support of CHF 1.75 million available to scale initiativesAquapreneur Innovation Initiative: CHF 15 million commitment to global water challenges HCL Group, a leading global conglomerate, and UpLink, the World Economic Forum’s early-stage innovation initiative, have announced the winners of the ‘Water Resilience Challenge,’ the fourth in a series of five challenges under the five-year, CHF 15 million Aquapreneur Innovation Initiative launched by HCL Group. The announcement marks a significant step in the ongoing mission to address global water challenges through innovation and entrepreneurship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121697759/en/ Roshni Nadar Malhotra, Chairperson of HCL Group, congratula

illumynt Appoints Chris Tejeda as Chief Revenue Officer21.1.2026 15:47:00 CET | Press release

illumynt today announced the promotion of Chris Tejeda to Chief Revenue Officer (CRO), reflecting the company’s continued growth and expanding global footprint. In his new role, Tejeda will lead illumynt’s global revenue strategy, customer engagement, and strategic partnerships as demand accelerates for secure, technology-driven IT Asset Disposition (ITAD) solutions. “Chris has been instrumental in aligning our commercial strategy with the evolving needs of hyperscale and enterprise customers,” said CEO Joerg Herbarth. “As AI accelerates infrastructure refresh cycles and raises the bar for security and compliance, his leadership will be critical to scaling illumynt with focus, transparency, and customer trust.” Tejeda brings extensive experience in enterprise technology services and has played a key role in illumynt’s recent momentum, including significant revenue growth and the expansion of advanced capabilities across AI/GPU diagnostics, automation, and value recovery. View source ve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye